Deverra’s lead clinical asset, Dilanubicel, has shown significantly improved remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. They are just one clinical trial away from potential FDA approval.
Organizations Involved
None
Founders
Michael Yurkowsky, Colleen Delaney, Andrew “Al” Kucharchuk
Company Description
Deverra is a clinical-stage biotech company committed to providing universal donor treatments, opening doors for accessible & affordable immune cell therapies for cancer & other life-threatening illnesses.